Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study

Cayley Russell1*, Frishta Nafeh1, Michelle Pang1, Shanna Farrell MacDonald2, Dena Derkzen2, Jürgen Rehm1,3,4,6,7,8 and Benedikt Fischer3,9,10,11

Abstract

Background: Incarcerated populations experience an elevated prevalence of opioid use disorder (OUD). Federal correctional institutions in Canada have increasingly treated OUD among correctional populations via opioid agonist treatment (OAT) – an evidence based pharmacotherapy that works to reduce drug use and related health harms. However, there is limited evidence regarding incarcerated individuals’ experiences with institutional-based OAT, as well potential OAT-related community release prospects. This information is important for optimal treatment retention and improved health. To address this knowledge gap, we conducted a longitudinal follow-up study examining OAT-related experiences among federally incarcerated individuals before and after community release. This article focuses on the baseline (pre-release) data.

Methods: This mixed-methods study examined OAT-related experiences and release prospects among \( n = 46 \) individuals scheduled for community release, recruited from seven federal prisons located in Ontario, Canada. Participants underwent a comprehensive interviewer-administered on-site assessment, including quantitative and qualitative items. Assessment data was furthermore linked to administrative correctional data. Data were analyzed using thematic qualitative and descriptive quantitative approaches.

Results: Participants had complex histories with opioid use including related negative health outcomes. Experiences with institutional OAT were divergent and provision was not standardized; those with OAT engagement pre-admission did not experience many challenges, whereas those initiating OAT during incarceration experienced barriers such as treatment waitlists and adverse process experiences. Most participants expressed a preference for buprenorphine-naloxone over methadone, but described difficulties accessing it. Participants were keen to transition into community-based treatment, yet envisaged prospective barriers and facilitators concerning successful reintegration and treatment continuity.

Conclusions: Major barriers towards the current administration of OAT in federal correctional systems in Canada exist, including extensive waitlists, non-standardized practices, and challenges accessing preferred OAT formulations;
Background

Correctional populations experience an elevated prevalence of substance use-related issues, including problematic opioid use and opioid use disorder (OUD) [1–4]. Globally, substance use disorders among correctional populations have been estimated at 30 and 51% among males and females, respectively [1]. Despite a zero-tolerance policy for substance use in correctional institutions, substance use remains prevalent during incarceration periods, with global rates estimated around 20–40% [5–7]. Specifically, in Canada, over 70% of a sample of federally incarcerated men reported having a substance use problem and 16% reported being under the influence of opioids on the day of their offence between 2006/07–2008/09 [8–10]. Similarly, four-fifths of federally incarcerated women reported a substance use problem at the time of admission, and these rates were even higher among Indigenous women, likely in part to the longstanding negative impacts of colonialism [11–14]. Other Canadian data confirm high rates of opioid use prior to and during incarceration, as well as a high prevalence of OUD diagnoses among correctional populations [11, 15–18]. Further, OUD within Canadian correctional facilities has been increasingly linked with adverse outcomes including overdose incidents [19]. For instance, a total of 330 overdoses occurred within federal correctional institutions between 2012/2013 and 2016/2017; of the 7% of overdoses which were fatal, over 90% were due to opioids, with 36% involving fentanyl [20].

Within the community and correctional settings, the primary treatment for OUD in Canada is opioid agonist treatment (OAT), including methadone and/or buprenorphine-naloxone (Suboxone) formulations. OAT is an evidence-based, safe, and effective treatment for OUD which reduces withdrawal symptoms and opioid use and related risks [21–25]. Canadian clinical guidelines now recommend buprenorphine-naloxone-based OAT as the first-line treatment for OUD, while federal correctional institution OAT policies refer to these guidelines as a standard [20, 21], and international human rights guidelines emphasize equal rights for individuals to be provided with the same healthcare (including OAT) as received in the community [26–30]. However, historically, the implementation and uptake of OAT programs in correctional settings has been restricted, and a variety of structural, cultural, and organizational barriers have rendered them far limited and inferior in quality compared to community-based OAT [29, 31, 32]. For example, correctional institutions often face qualified healthcare staff shortages, and institutional policies typically focus on security concerns and abstinence-based treatment approaches based on traditional tenets of punishment and risk-reduction over health interventions, including penalization of individuals for drug use during incarceration [31, 33].

Thus, the provision of OAT in correctional settings remains limited. In the United States, only 40 out of over 5000 local/county jails or state/federal prisons offered OAT as of 2016, rendering the vast majority of incarcerated individuals with OUD unable to access a vital evidence-based treatment and leaving them vulnerable to withdrawal and other adverse events [34–38]. In Canada, correctional OAT demand and coverage has substantially increased over recent years; OAT is now available in all federal prisons and most provincial/territorial correctional settings [29, 39]. For instance, Correctional Service Canada (CSC) (the Canadian federal government agency responsible for administering criminal sentences of 2 years or more to incarcerated adults), has provided methadone to federally incarcerated individuals with OUD for over 20 years, further expanding the program to offer buprenorphine-naloxone in 2008 [40–44]. The total number of OAT patients across federal correctional institutions has more than doubled from 920 in 2016, to 2481 in January 2021, and approximately 15% of all federally incarcerated individuals now receive OAT [45, 46]. OAT formulation options have recently expanded to include different buprenorphine-naloxone preparations (e.g., sublingual tablet and/or sublingual/buccal film) as well as extended-release injectable buprenorphine [Sublocade] [20, 46].

OAT is associated with a number of positive outcomes among correctional populations with OUD, such as increases in drug treatment entry and retention, reductions in drug – and opioid – use, as well as reduced recidivism, overdose, and mortality [35, 47–50]. Specifically, a recent systematic review found that methadone treatment initiated during incarceration is associated with significantly higher post-release community-based OAT engagement, and reductions in illicit opioid use and injection drug use [49]. In Canada, correctional OAT involvement has been associated with a decreased likelihood of overdose and non-medical prescription opioid use [51], as well as a lower risk of returning-to-custody [11], and lower rates of violent and non-violent offences.
Moreover, a correctional health care service evaluation (2017) found that individuals participating in CSC’s OAT program reported a lower prevalence of injection drug use, needle-sharing, positive urinalysis tests, serious disciplinary offences, and an increase in educational program participation during incarceration [53].

These statistics underscore both the importance of providing OAT to correctional individuals with OUD, and the need for effective transition of inter-institutional (e.g., correctional transfers) and community-based OAT care after release; the latter has been identified as a crucial point where OAT care (e.g., retention) is commonly compromised or interrupted [54–59]. Furthermore, correctional populations face high odds of substance use-related relapse and overdose upon release, which can be mediated by OAT provision [48, 60]. Given the high rates of OUD among correctional populations, and high proportion of individuals receiving OAT in CSC, OAT is recognized as an essential health care intervention, yet with considerable risk for continued substance use, relapse, and overdose risk both during and post-incarceration if not provided effectively and/or continuously [51]. The continuous provision of OAT to incarcerated individuals with OUD is therefore especially pertinent, given these adverse health risks as a possible outcome of ineffective OAT care. However, there is a lack of information on individuals’ experiences with OAT care during incarceration and community release prospects and related factors which may influence outcomes, especially in the Canadian context. In order to address this knowledge gap, we conducted the present study with a cohort of federally incarcerated individuals receiving OAT care and scheduled for community release across institutions in Ontario, Canada.

**Methods**

**Study design**

This paper focuses on the baseline results of a longitudinal, mixed-methods observational study examining OAT-related experiences among a multi-institutional sample of federally incarcerated individuals. Two separate assessments were conducted, occurring at two separate time points: during the sample’s 1) pre-release incarceration period (baseline); and 2) community transition period following-release (follow-up). The study was conducted independently by an external academic team and field researchers, with logistical support from CSC.

**Eligibility**

Study eligibility criteria included individuals who were: 1) currently incarcerated at one of the seven Ontario-based CSC institutions; 2) diagnosed with OUD as per clinical requirement to receive institutional OAT care; 3) involved in CSC’s OAT program for at least 3 months; 4) given a statutory release or parole eligibility date scheduled within 6 months of the baseline (pre-release) interview; 5) with an expected release location within Ontario; and 6) willing and consenting to participate in both the study’s baseline (pre-release) and follow-up (post-release) assessments.

**Recruitment and consent**

Participant recruitment and institutional access/assessment space was facilitated with the assistance of institutional site contacts at each CSC institution. An up-to-date list of individuals on OAT with release dates scheduled within the next 6 months was provided by CSC to institutional site contacts (e.g., healthcare administrators) at each institution. These site contacts then approached the individuals listed and provided them with a study flyer that included a toll-free study line allowing individuals to anonymously contact the research team if they were interested in participating. The study flyer was also openly posted in the healthcare unit for anyone to see and follow-up with the research team if interested. Further, individuals also had the option of expressing interest to the study staff directly for study participation screening procedures.

The research team (two field researchers) arranged approximately week-long field visits at each CSC institution for study participant recruitment and assessments. Upon arrival, individuals who had expressed interest in participating met with the researchers to be screened for eligibility where they provided their federal fingerprint serial (FPS) number, as well as a pseudonym, and were given a study ID number to identify them on all study documents. The eligibility screening consisted of a brief 8-question protocol. Upon determination of an individual’s eligibility, the research team then scheduled participants to complete the main assessment at a predetermined time (aligned with institutional schedules) during the same institutional research visit.

Participants were informed that the study was being confidentially conducted by an external research group (i.e., not affiliated with CSC) without individual study information being shared with anyone outside the research team, including any CSC personnel. No personal identifying information was collected; participants’ FPS numbers were the only identifiers used to link administrative data from CSC databases, and the pseudonym participants provided (and corresponding study ID given) was used on all subsequent study documents and analysis. Informed written consent was obtained from all participants, for both the baseline and follow-up assessments, for explicit linkage of individual administrative data from CSC databases, as
well as for future contact with the participant and their community parole officer to facilitate the follow-up assessment. Study participants were offered a $50 honoraria upon completion of the follow-up assessment (as honoraria could not be provided during incarceration as per CSC guidelines) [61].

Data collection and assessment tools
Between January 15th and March 31st, 2019, the research team visited each of the participating seven (6 men, 1 women) federal CSC institutions located across Ontario (see Appendix 1, Fig. 2 for a map and institutional security levels) to conduct the baseline (pre-release) assessments with study participants. Data collection was completed over the course of approximately 1 week per institution, and each assessment was completed in a single session (approximately 45–90 min in time). All assessments were conducted in a private interview room with security arrangements; study participants were provided with a 'pass' which allowed them to attend the assessment at the time scheduled.

The baseline assessment consisted of a quantitative (pen-and-paper), interviewer-administered survey, followed by a qualitative (semi-structured, audio-recorded, one-on-one interview-based) component. The survey took approximately 15–30 min to complete. The data timeframe included a primary focus on two temporal snapshots: 1) ‘30 days prior to incarceration’ and 2) ‘past-30 days’ (during incarceration). The qualitative interview took approximately 30–60 min and consisted of 9 open-ended principal questions (see Appendix 2 for interview guide).

Additionally, using participants’ FPS numbers, we linked select complementary aggregate administrative data, mainly comprising basic socio-demographic, criminogenic and institutional-behavioral data for each participant, extracted and provided from two primary CSC-based databases: the Offender Management System (OMS) which maintains all individual records and data (e.g., socio-demographics) [62]; and the Computerized Assessment of Substance Abuse (CASA) database which documents substance use among individuals admitted to federal custody [63–65]. The CASA assessment is based on ratings obtained via three standardized tests, and is a standardized, computer-assisted, self-administered assessment completed by all individuals admitted to federal custody during the intake process. These data variables were stripped of any identifying information and shared via an encrypted file transfer using participants’ FPS numbers.

Data processing and analysis
Hardcopy survey documents were stored in a locked filing cabinet, and all survey data were entered into an encrypted excel database for data processing and analysis. Basic descriptive statistics (e.g., mean and frequency values) were performed on participant characteristics and behavioral data, using a combination of participant survey and select complementary administrative CSC data.

All audio-recorded interviews were transcribed verbatim and imported into qualitative data management software (NVivo 12). Audio recordings were deleted subsequent to transcription. Any potentially identifying information that may have been revealed during the interview process (e.g., references to city or service names, etc.) were removed from the data. Qualitative interview data underwent an inductive thematic analysis process, whereby key initial themes were identified, and a preliminary codebook was developed in Excel [66]. Specifically, one member of research team (CR) open-coded the transcripts based on the initial codebook to identify common responses to the study's research questions. Following extensive discussion among the research team, the initial codes were then refined and applied to the data. Additional codes emerging from the data were subsequently added to the codebook as part of the iterative coding process [67]. In order to ensure transparency and consistency in data analysis, the research team utilized inter-coder reliability whereby an independent coder (FN) coded a randomly selected sub-sample (20%) of the transcripts [68], and any codebook revisions and coding queries were resolved with the team based on ongoing discussion. The final qualitative themes and sub-themes presented were informed by multiple participants conveying similar sentiments and statements until data saturation was met [69, 70]. All themes were narratively summarized for results and are further illustrated and substantiated by select participant quotes.

Ethics
Study procedures were approved by the Centre for Addiction and Mental Health (CAMH) Research Ethics Board (REB: #013–2018).

Results
Sample
A total of n=68 potentially eligible individuals were screened for participation across the seven CSC institutions; n=22 participants were not included as they either were ineligible, not interested, or could not attend their scheduled assessment. The final study sample included
n = 46 (40 men and 6 women) participants. The following briefly summarizes variables from the baseline survey data in conjunction with administrative CSC data.

Quantitative results
Socio-demographics (see Table 1)
The sample’s mean age was 36.4 years; the majority (87%) were men who reported their ethno-cultural/racial background as white (65%); 33% reported identifying as Indigenous. Most (65%) participants had less than high school education. Prior to incarceration, 54% reported having unstable accommodation, and the majority (83%) participated in illegal activities (e.g., selling drugs, robberies, debt collecting, other income generation crimes, etc.) as their main source of income.

Criminogenic and institutional-behavioral characteristics (see Table 2)
Participants’ mean sentence length was 3.1 years, and 39% were serving a second or subsequent sentence. The most common offence type for which participants were serving time was ‘violent’ (35%), followed by ‘drug-related’ (22%). Nearly half (44%) had a history of institutional charges and 22% had an institutional incident record related to drug contraband. Nearly one in five (17%) had a positive illicit substance urinalysis test result at some point during their incarceration period, with 8% positive for opioids.

Table 1 Sociodemographic characteristics of study sample (N = 46)

| Characteristic                        | % (n) |
|--------------------------------------|-------|
| Gender                               |       |
| Men                                  | 87% (40) |
| Women                                | 13% (6) |
| Age (Mean ± SD)                      | 36.4 ± 7.7 |
| Race                                 |       |
| White/other                          | 67% (31) |
| Indigenous                           | 33% (15) |
| Less than high school diploma        | 65% (30) |
| Unstable accommodation prior to incarceration | 54% (25) |
| Main source of income (30 days prior to incarceration) |       |
| Illegal activities                   | 83% (38) |
| Social assistance                    | 61% (28) |
| Family/friends                       | 33% (15) |
| Legal employment                     | 26% (12) |
| Illegal work                         | 26% (12) |
| Personal savings                     | 17% (8) |
| Other                                | 9% (4) |

Table 2 Criminogenic and institution-specific characteristics of study sample (N = 46)

| Characteristic                        | % (n) |
|--------------------------------------|-------|
| Security level at interview          |       |
| Medium/maximum                       | 78% (36) |
| Minimum                              | 22% (10) |
| Offence type                         |       |
| Violent                              | 35% (16) |
| Drug-related                         | 22% (10) |
| Robbery                              | 22% (10) |
| Property-related                     | 15% (7) |
| Non-violent                          | 7% (3) |
| Sentence length (years)              |       |
| Mean ± SD                            | 3.1 ± 1.3 |
| Number of sentences                  |       |
| 1                                    | 61% (28) |
| 2+                                   | 39% (18) |
| Institutional activities             |       |
| Correctional Programming             | 83% (38) |
| Education                            | 39% (18) |
| Employment                           | 20% (9) |
| History of institutional charges     |       |
| 44% (20)                             |       |
| Institutional incidents              |       |
| 46% (21)                             |       |
| Drug contraband                      | 22% (10) |
| Institutional urinalysis             |       |
| Positive for illicit drug use        | 17% (6) |
| 8% (3)                               |       |

* Data acquired from CSC; Violent offences include homicide, sex-related, assault, and other
b Only one participant had a maximum security classification
c Timeframe was between initial admission to federal custody and interview date. Correctional programming entails multi-target skill-based learning programs that address multiple risk factors linked to individual criminal behaviour, offered at moderate and high-risk intensity levels

Substance use and treatment (see Table 3 and Fig. 1)
Most (84%) participants had a ‘substantial’ or ‘severe’ substance use problem assessed at admission. Half (50%) reported both a lifetime, and recent pre-incarceration history of injection drug use. About half (44%) were engaged in OAT pre-incarceration with almost all receiving methadone-based OAT. Methadone was also the most commonly used institutional OAT formulation (67%). Over half (57%) had a history of poly-substance use; stimulants (78%), prescription opioids (78%), and heroin/other illegal opioids (67%), were the most commonly used drugs pre-incarceration, while cannabis use (28%) was the most common during incarceration.
Qualitative results

Qualitative data results are presented under the following overarching themes: opioid use initiation and trajectories; opioid-related health effects; benefits of OAT; OAT formulation preferences; diverse experiences accessing institutional OAT; institutional and physician discrepancies; potential barriers to community reintegration; and potential facilitators to community reintegration.

Opioid use initiation and trajectories

All participants reported experiences with opioid use prior to incarceration, and many indicated that they commonly engaged in polysubstance use. While the majority of participants described experimenting with drugs (including opioids) during adolescence or early adulthood, just under half reported being introduced to opioids through legitimate prescriptions, commonly for pain management and/or other medical reasons. Most of these participants suggested that they had been unaware of the addictive potential of opioids, and that they had been prescribed pharmaceutical opioids for a period of time before their use patterns changed. The trajectory of opioid use for many accelerated after tolerance increased and/or their provider stopped prescribing them. As such, many reported increasing their use and/or switching to illicitly-sourced opioids for access, affordability, or the need to utilize more potent opioids:

“I threw my back out and it started with doctors giving me [Percocet], and it just progressed from there ... I got cut off from the Percs from my doctor, so I turned to the streets for them ... I started taking Oxy 10’s, 20’s, 40’s, and just 80’s.” (Participant 35)

Similarly, progressive changes in route of administration were reported by most respondents. The majority had started with oral use and over time graduated to inhalation, and in some instances, injection use of opioids in order to achieve desired effects.

Opioid-related health effects

Most respondents indicated that their opioid use caused various physical harms, such as track (injection) marks, abscesses, dental, and weight-related problems, as well as drowsiness, tolerance, dependence, and withdrawal. In some cases, participants contracted infectious diseases such as Hepatitis C from sharing drug paraphernalia:

“I did obtain Hep C. However, I took the treatment when I was here, on my first federal bit. I got out and I did inject again, because I relapsed ... but if you were to take a blood sample you would see that I have the antibodies, but I’m not contagious.” (Participant 28)

While many participants described witnessing friends, peers, or family members experience overdoses, a minority indicated they had personally experienced opioid overdoses (within the community and/or during incarceration).

In many cases, participants suggested that opioids had also impaired their mental well-being, citing symptoms of memory loss, hallucinations, depression, anxiety, and/or suicidal thoughts. Several respondents also reported having co-morbid mental health symptoms/diagnoses, some of which may have been exacerbated by their opioid use:

“I attempted suicide in the past year four times. I’m not saying that just to get sympathy, but yeah, I think it has [impacted my mental health] to a

Table 3

| Characteristic                                      | % (n) |
|----------------------------------------------------|-------|
| Severity of substance use at admission<sup>a</sup> | 84% (36 of 43) |
| History of polysubstance use<sup>b</sup>            | 57% (26) |
| History of injection drug use<sup>b</sup>           | 50% (23) |
| Lifetime<sup>b</sup>                                | 50% (23) |
| 30 days prior to incarceration<sup>b</sup>           | 37% (17) |
| Non-OAT substance use services used (30 days prior to incarceration)<sup>b</sup> | 46% (21) |
| Harm reduction services                             | 17% (8) |
| Support groups                                      | 15% (7) |
| Inpatient treatment                                 | 9% (4) |
| Engagement in OAT (30 days prior to incarceration)  | 44% (20) |
| Type(s) of OAT (30 days prior to incarceration)<sup>ac</sup> | 95% (19 of 20) |
| Methadone                                           | 5% (1 of 20) |
| Both Methadone and buprenorphine-naloxone           | 10% (2 of 20) |
| Hydromorphone                                       | 5% (1 of 20) |
| Entered CSC on OAT                                   | 39% (18) |
| Type(s) of OAT during CSC incarceration<sup>b</sup> | 67% (31) |
| Methadone                                           | 33% (15) |

<sup>a</sup> Responses not mutually exclusive
<sup>b</sup> Data acquired from CSC
<sup>c</sup> Responses out of n = 43 participants who had this data; Severity of substance use is determined using CASA. Harm reduction category includes use of either needle exchange, safer use kits, naloxone kits, etc.; Outpatient treatment category includes either group therapy, one-on-one therapy/counseling, relapse prevention; Inpatient treatment category includes residential treatment, rehabilitation, detoxification/withdrawal management; Support groups include self-help or mutual aid groups such as alcoholics anonymous, narcotics anonymous, etc.
the certain degree. I've only recently developed bipolar disorder ... maybe that's the impact that the drugs have, I don't know. I have PTSD." (Participant 42)

Benefits of OAT
The majority of participants had a history of pre-incarceration engagement in OAT. While just under half were OAT-involved immediately prior to incarceration, others had gone on-and-off OAT for several years, both within the community and during different incarceration periods. Regardless of their OAT history, most respondents suggested that overall, OAT had been beneficial and helped them avoid withdrawal symptoms, temper substance use cravings and triggers, as well as reduce their opioid use:

"Some of my urges, like cravings, are just gone, and when I do some of the things that triggered me before, they don't trigger me anymore. When I do get triggered, I have more control over the cravings." (Participant 36)

Specific benefits included the structure that OAT provided in participants' lives by giving them a daily purpose and routine. Many indicated that having to consistently provide negative urinalysis tests gave them incentive to refrain or reduce their substance use:

"Yeah, like I said, it puts structure in my life. The weekly urinalysis and that, like, really, is what mostly did it for me. 'Cause like, I got embarrassed about giving dirty urines. You know, going in there asking for help and then just constantly giving dirty urines. So that's something that's really put me on the straight and narrow." (Participant 04)

OAT formulation preferences
Preferences for buprenorphine-naloxone versus methadone-based OAT varied among participants. The majority reported that while methadone was better known and more utilized since it had been available for longer, they preferred buprenorphine-naloxone. These participants explained that they not only experienced fewer long-term side effects from buprenorphine-naloxone, but that they were also under the impression that it safeguarded against using other opioids due to its abuse-deterrent formulation (i.e., the naloxone component). Conversely, a few participants explained that since one can use other opioids while on methadone, it was used by some to reduce opioid use and consequent spending, and to avoid related withdrawal symptoms:

"While I was on methadone, I was still using heroin. I was, like, literally still using it. So it kind of was helping, but at the same time, it wasn't. Methadone really wasn't working for me while I was in the community. I kind of gave up on it and just said, forget it, and I continued to do drugs. The fact that you can drink methadone and still do drugs, it's not helping. Whereas, like, with the Suboxone, I was told that if you use Suboxone and do drugs that you go into immediate withdrawal." (Participant 12)

Additionally, most participants described methadone as being associated with more stigma and having worse health effects such as dental decay, weight gain, low testosterone, decreases in libido, lethargy, organ (e.g., liver and kidney) problems, and headaches. In addition, many perceived methadone to cause more severe withdrawal
and dependence symptoms, describing it as ‘liquid handcuffs’ or stating that they could ‘feel it in their bones.’ It was suggested that ceasing or weaning off of it was extremely difficult due to the physical effects:

“Methadone was, I think, harder to come off with than any other drug. Harder to come off with than Suboxone. I've done Suboxone while I was in the provincial system. I was doing it every day for about thirty days, I was buying it off another inmate. But even coming off of that was nothing compared to coming off of Methadone. Coming off of Methadone was worse than coming off heroin, oxycodone, percs, fentanyl. Yeah, it was bad.” (Participant 12)

**Diverse experiences accessing institutional OAT**

In terms of receiving institutional OAT, two overarching and divergent experiences were expressed. One the one hand, participants who were engaged in OAT immediately pre-incarceration commonly described an easy and relatively seamless transition from community-based into institutional-based OAT. Participants only had to prove when they had taken their last dose (e.g., present paperwork or confirmation with their community doctors), which typically took anywhere from 1 day up to 2 weeks. This was the case for about half of the participants with prior OAT engagement, during which time they experienced treatment interruptions and related adverse effects, including withdrawal:

“It was pretty horrible actually. When I had gotten arrested I had just gotten my carries [take-home OAT] and they were all at my house. And so they wouldn’t give me any methadone for, like, I think it was almost two weeks before I got my methadone again. It was horrible.” (Participant 21)

Conversely, those who were not on community-based OAT immediately prior to their current incarceration (i.e., just over half of participants), or who had experienced medication disruptions at the provincial correction point-of-entry to the criminal justice system, experienced significant challenges in accessing CSC’s OAT program. These participants reported extensive wait times (in most instances amounting to multiple months) before they were able to enroll in institutional OAT. This was for several reasons, including participants being housed at assessment institutions where they were not allowed to initiate OAT until transferred to their main institution. Other reasons included institutional policies which stipulated maximum numbers of OAT patients at any given time (i.e., waitlists), where institutions could not induct anyone else on OAT if they had reached their operational capacity:

“They said that there was too many people on it, and that they didn’t have enough room in the area where they did the methadone or Suboxone to add anybody else. They put me on a waiting list that never went any higher, basically. So I waited for four months and then I asked to get transferred to where I could go to get it.” (Participant 36)

A number of the participants who were waitlisted consequently reported negative effects such as buying and using clandestine drugs, and receiving institutional charges for drug contraband during incarceration. In some cases, a few indicated they contracted infectious diseases (e.g., Hepatitis C) from sharing drug use equipment and/or overdosed during these waiting periods:

“It did take almost a year to get on [OAT], so the wait period was very lengthy. And I did get in a lot of trouble over that year while I was trying to get on it, including that overdose.” (Participant 22)

Additionally, some participants indicated they had used diverted OAT medications and/or other opioids/drugs during their current sentence, some of whom had done so in order to self-medicate and/or to reduce withdrawal symptoms while waiting for OAT:

“When I came in, I went through the sickness. And I was sick probably, frigging four months, five months. And I'd still use when drugs came in ... I started spending an awful lot of money ... I ended up beside a cellmate and he had tons and tons of drugs. And I had a rig [syringe]. So, he started giving me drugs to use the rig. And believe it or not, that's where I ended up getting Hep C. It was in prison.” (Participant 40)

**Institutional and physician discrepancies**

Beyond excessive waiting periods to initiate OAT, key discrepancies between institutional processes and OAT physicians were reported. Overall, nearly all participants reported that physician visits were unreliable and infrequent (commonly only once a month, and in some instances not for several months), and that waiting periods varied across institutions. This was detrimental for those who experienced problems (e.g., dosing, etc.) with their current OAT regimen and who required physician consults, but had to wait a month or more to do so. Also, participants reported inter-institutionally discrepant experiences with OAT practices and/or related interactions with health care staff. OAT processes were inconsistent, non-standardized, and appeared to be based on individual institutional policies and/or medical staff preferences and/or capabilities, rendering a diverse picture of the day-to-day operations of correctional OAT care. For example,
introduced to small doses of buprenorphine-naloxone, would slowly wean off methadone while gradually being transitioned through 'micro-dosing', where participants induct buprenorphine-naloxone, which was experienced as highly undesirable due to withdrawal symptoms. However, some physicians would allow an alternative transition process through 'micro-dosing', where participants would slowly wean off methadone while gradually being introduced to small doses of buprenorphine-naloxone, which was more desirable. Reasons for wanting to switch from methadone to buprenorphine-naloxone included the extensive stigmatization associated with methadone, where many receiving methadone-based OAT felt ostracized and looked down upon by peers, as well as by correctional staff. It was also suggested that many individuals who would potentially benefit from OAT would not engage with it due to its stigma, and an inability to receive buprenorphine-naloxone. Generally, many participants were frustrated with the lack of personal agency and inability to freely choose the OAT formulation they felt would work best for their health and treatment:

“When I got here I talked to the doctor about getting off methadone and going on Suboxone, and I was told that I wouldn't be able to do that until a month before I was getting released. So I always thought that the program is – you know, it should be up to you which one you want to choose.” (Participant 21)

Several institutions were also in the process of switching from the sublingual buprenorphine-naloxone tablet to the buccal film regimen during the study as a means to mitigate diversion. Among participants who had received the new formulation, some indicated that they disliked its taste, but that it had longer-lasting effects compared to the pill format. This was primarily due to health care staff in some institutions crushing the buprenorphine-naloxone tablets before administration in order to prevent potential diversion. Many participants indicated that this procedure severely compromised the medication's strength, resulting in subsequent withdrawal symptoms:

“I wanted to get off the methadone, and I told [the nurse] that I wanted to switch over to Suboxone because [it] is not as bad on your overall system ... She said 'oh, if you don't have a heart problem, like palpitations or some kind of cardiovascular problem that the methadone causes, which I did have, um, you weren't a candidate for going on Suboxone'. And that was that. Like you're basically telling me I have no choice but to be a slave to the methadone.” (Participant 05)

Another discrepancy between institutions and individual OAT physicians' practices revolved around the specifics for switching between OAT formulations. Most physicians required participants to undergo a three-day detoxification period from methadone before they could induct buprenorphine-naloxone, which was experienced as highly undesirable due to withdrawal symptoms. However, some physicians would allow an alternative transition process through 'micro-dosing', where participants would slowly wean off methadone while gradually being introduced to small doses of buprenorphine-naloxone, which was more desirable. Reasons for wanting to switch from methadone to buprenorphine-naloxone included the extensive stigmatization associated with methadone, where many receiving methadone-based OAT felt ostracized and looked down upon by peers, as well as by correctional staff. It was also suggested that many individuals who would potentially benefit from OAT would not engage with it due to its stigma, and an inability to receive buprenorphine-naloxone. Generally, many participants were frustrated with the lack of personal agency and inability to freely choose the OAT formulation they felt would work best for their health and treatment:

“When I got here I talked to the doctor about getting off methadone and going on Suboxone, and I was told that I wouldn't be able to do that until a month before I was getting released. So I always thought that the program is – you know, it should be up to you which one you want to choose.” (Participant 21)

Several institutions were also in the process of switching from the sublingual buprenorphine-naloxone tablet to the buccal film regimen during the study as a means to mitigate diversion. Among participants who had received the new formulation, some indicated that they disliked its taste, but that it had longer-lasting effects compared to the pill format. This was primarily due to health care staff in some institutions crushing the buprenorphine-naloxone tablets before administration in order to prevent potential diversion. Many participants indicated that this procedure severely compromised the medication's strength, resulting in subsequent withdrawal symptoms:

“I wanted to get off the methadone, and I told [the nurse] that I wanted to switch over to Suboxone because [it] is not as bad on your overall system ... She said 'oh, if you don't have a heart problem, like palpitations or some kind of cardiovascular problem that the methadone causes, which I did have, um, you weren't a candidate for going on Suboxone'. And that was that. Like you're basically telling me I have no choice but to be a slave to the methadone.” (Participant 05)

Another discrepancy between institutions and individual OAT physicians' practices revolved around the specifics for switching between OAT formulations. Most physicians required participants to undergo a three-day detoxification period from methadone before they could induct buprenorphine-naloxone, which was experienced as highly undesirable due to withdrawal symptoms. However, some physicians would allow an alternative transition process through 'micro-dosing', where participants would slowly wean off methadone while gradually being introduced to small doses of buprenorphine-naloxone, which was more desirable. Reasons for wanting to switch from methadone to buprenorphine-naloxone included the extensive stigmatization associated with methadone, where many receiving methadone-based OAT felt ostracized and looked down upon by peers, as well as by correctional staff. It was also suggested that many individuals who would potentially benefit from OAT would not engage with it due to its stigma, and an inability to receive buprenorphine-naloxone. Generally, many participants were frustrated with the lack of personal agency and inability to freely choose the OAT formulation they felt would work best for their health and treatment:

“When I got here I talked to the doctor about getting off methadone and going on Suboxone, and I was told that I wouldn't be able to do that until a month before I was getting released. So I always thought that the program is – you know, it should be up to you which one you want to choose.” (Participant 21)

Several institutions were also in the process of switching from the sublingual buprenorphine-naloxone tablet to the buccal film regimen during the study as a means to mitigate diversion. Among participants who had received the new formulation, some indicated that they disliked its taste, but that it had longer-lasting effects compared to the pill format. This was primarily due to health care staff in some institutions crushing the buprenorphine-naloxone tablets before administration in order to prevent potential diversion. Many participants indicated that this procedure severely compromised the medication's strength, resulting in subsequent withdrawal symptoms:
Finally, some participants discussed contempt for the OAT program, and explained that the challenges of institutional OAT care engagement, including wait times to engage in OAT care, achieving a comfortable dose, and the inability to choose their preferred OAT medication, fundamentally undermined the benefits of the program and resulted in negative health outcomes. Participants thus suggested and urged for operational changes to improve it:

“These overdoses are happening because there’s no real alternative. The methadone program takes forever to get on, and there’s a stigma attached to it. So they should start allowing more people not only to switch from methadone to Suboxone ... And then allowing more people just to join, to get on ... And I think they need to find a better way to deliver it in the mornings ... But a lot of those guys, they want to come off it, or they want to switch to the Suboxone ... So I think that will be the biggest thing that I would change.” (Participant 25)

Potential barriers to community reintegration
When considering plans and goals towards their release into the community, most participants indicated a desire to improve their health, find a job, reconnect with family and friends, and become participating members of society. Yet, participants expressed a mix of emotions such as dread, anxiety, and apprehension, combined with enthusiasm and excitement towards their impending release. Specifically, some expressed fear that they would relapse to drug (and opioid) use and end up losing support from their families and return to prison:

“I’ve got anxiety and I’m feeling really anxious, I guess. Because in here I’ve got nothing but to gain [sic] towards my release, out there, I’ve got everything to lose. Like in here I’ve got my family and everything supporting me. Out there, if I go back to drug use, or crime, I come back to prison, and then it’s all gone.” (Participant 15)

Regarding their post-release plans for OAT, about four-in-five participants indicated that they planned on engaging with OAT in the community immediately after release, with nearly half of those expressing that they expected to remain on OAT for at least a year. Others indicated that while they expected to remain on OAT in the short-term, they would like to wean off OAT by the end of their parole period. However, some expressed nervousness regarding potential repercussions of ending OAT engagement prior to the end of their parole as it could conflict with formal stipulations of their correctional release plans, or be perceived as a sign of non-commitment towards addressing their substance use issues and successful community reintegration by their parole officer.

While the majority of participants indicated plans to remain engaged with OAT, they suggested several possible barriers to receiving continuous OAT care in the community, including stigma associated with OAT, the location of and lack of available transportation to OAT clinics, not having required identification/papers, difficulty in reconciling daily appointments with possible work schedules, and the possible cost of OAT care:

“I don’t know. I guess it would depend on like location maybe. I would imagine that everywhere in [city name], there’s got to be pharmacies that offer Suboxone. But if I had to live by myself – apparently like Suboxone is like $20.00 a dosage every day – so if I wasn’t working that could be an issue.” (Participant 15)

Some participants described uncertainty regarding release details which they suggested made it difficult to develop concrete OAT-related care plans in advance. For participants who anticipated living in a community-based residential facility (e.g., a halfway house) or residential treatment, it was common that they would not learn of release details until shortly before, as it depended on space availability. Some indicated that not knowing these details would prevent them from securing essential community-based services and supports, and emphasized the importance of timely release planning:

“It’s hard to picture anything without knowing where you have to put your head. You know what I mean? That’s the main thing ... from there it will all fall into place. Once you know where to put your head, you can go and accumulate your stuff.” (Participant 27)

The other major barrier to staying on OAT and accomplishing their release plans related to fears of running into past acquaintances, with half of participants expressing that their social connections and/or visiting known community OAT clinics might facilitate easy access to substances, and increase the risk for a potential relapse:

“First thing would be going to this clinic to do my urinalysis throughout the week. I’m worried because I’ve lived in [city name] my entire life and I know a lot of people and part of my problem is accessibility to drugs. So if I’m going there every day it’s only a matter of time before I start running into old acquaintances, people that I know, and they might have access to drugs for me.” (Participant 22)
**Potential facilitators to community reintegration**

Participants also indicated a few key potential facilitating factors that they suggested would help them reach their goals and effectively continue OAT after release. Securing a job and housing were among the top suggestions, as was the ability to receive OAT ‘carries’ (i.e., take-home doses of OAT medication) as quickly as possible so that they would be more flexible and able to balance their work or other responsibilities against the (e.g., daily) rigorous clinic attendance requirements to obtain their OAT medications. Other potential facilitators included access to substance use-specific treatments and support programs.

When asked if there was anything in particular that would support their post-release transition and allow them to reach their goals, the most common response indicated by about two-in-three participants - was familial support. Examples included relying on family members to drive them to their OAT and other appointments, as well as for housing, social, and financial support:

“My mum said if I have to get to the pharmacy or whatever, daily, like she would make sure I get there. Because I’m not allowed to drive. And I probably will be in, like counselling. And hopefully I’m on this Suboxone program and I can attain carries shortly after, so that I can continue the program without the daily interruption of appointments and the pharmacy.” (Participant 22)

Lastly, some participants expressed that one of the most important facilitators for community reintegration was personal motivation. Many participants spoke about how they had finally reached a point where they were determined and ready to commit to staying abstinent.

**Discussion**

This longitudinal, mixed-methods study examined experiences with opioid use, community- and institutional-based OAT, and related perspectives on community release among a sample of federally incarcerated individuals in correctional institutions in Ontario, Canada. Consistent with other studies involving correctional populations, the results indicated that most participants had self-reported mental health and substance use problems, as well as a longstanding and complex history of drug - and specifically opioid - use and related issues [1, 71]. Opioid use trajectories commonly included quick transitions to high-intensity opioid use, including frequent (e.g., daily) use of strong (e.g., fentanyl) opioids used intravenously, which negatively affected participants’ health, and in some cases was a contributing cause of their arrest and current incarceration. Additionally, participant experiences with OAT varied, both in the community as well as during incarceration, which shaped their perspectives on its efficacy, utility, and expectancies related to OAT engagement upon release into the community [2, 48]. Furthermore, notable characteristics of the study sample include a high proportion of young men (a third of whom were Indigenous) with high-risk (e.g., injection, sharing equipment, overdose, etc.) drug use patterns and histories, yet relatively short sentences. These characteristics are unsurprising given the longstanding impacts of drug prohibition in Canada and the specific criminalization of illicit drug use which has disproportionately impacted marginalized populations and contributed to the overrepresentation of Indigenous peoples in the Canadian correctional system [12, 72–74]. These factors point to an increased risk of substance use and health-related impacts both during incarceration and post-release. However, participants expressed that OAT was beneficial in terms of reducing drug cravings and use, as well as towards meeting their goals post-release. This implies the opportunity and need for adequate OAT treatment initiation and related care during incarceration, as well as continuous treatment provision during and throughout the community transition period.

As the study results substantiate, drug use prior to and during incarceration is common, despite institutional policies prohibiting contraband from entering institutions [11, 15–18, 75]. Participants detailed persistent substance use and related issues during incarceration, including as a means of pain management and to combat withdrawal symptoms, especially when they experienced OAT disruptions [76, 77]. Regarding OAT initiation and provision during incarceration, a number of key access barriers were reported. These are largely in line with existent literature highlighting programmatic, attitudinal, and systemic barriers to correctional institution-based OAT and healthcare provision. These include a lack of professional skills, capacity, and resources (including qualified staff), restrictive policies, logistical obstacles such as institutional movement schedules, security concerns including OAT diversion, and a general lack of support and resources for treatment-oriented care in an environment generally shaped by risk reduction [29, 31, 78–80].

Importantly, the most common barrier reported related to extensive waiting periods regarding resuming or initiating institution-based OAT care during which time participants were at risk of experiencing withdrawal symptoms and overdose events, which they commonly had to endure with limited clinical management or oversight. These issues were sometimes aggravated
by individuals entering federal correctional institutions through provincial correctional systems first (e.g., individuals commonly present to provincial correctional institutions upon arrest and are held in remand while they await sentencing prior to transferring to federal institutions), where OAT prescribing practices and polices are diverse and non-standardized [33]. These issues have been identified by a recent human rights complaint [81], but they also categorically conflict existing clinical guidelines for community-based OAT (which does not recommend withdrawal management as a safe or appropriate treatment option), and contravene standing recommendations for seamless access to OAT for Ontario-based correctional populations [21, 33, 82]. As such, it can be seen as imperative that both provincial and federal correctional institutions consistently screen for OUD upon admission and actively work towards eliminating waitlists to ensure that all individuals who require OAT have immediate access, and do not need to undergo unnecessary withdrawal and related discomforts and risks for serious adverse health outcomes [83, 84].

Our results also demonstrated that even while national federal correctional (CSC) guidelines on institutional OAT provision exist [20], implementation differs across institutions (e.g., in regards to dosing, administration, processes, formulations, physician practices, etc.). Many physicians limited access to buprenorphine-naloxone in particular despite participants’ preference for this OAT formulation due to its perceived benefits. Other qualitative studies have suggested comparable preferences for buprenorphine-naloxone over methadone among both community and correctional-based populations, with methadone often linked to more negative health experiences and perceptions [85–89]. Furthermore, participants described methadone as being particularly stigmatized, which may have impacted individual’s decisions around OAT engagement. For instance, participants described experiencing negative judgments for being engaged in methadone, yet experienced major access barriers to buprenorphine-naloxone, which may have kept individuals with OUD from engaging in OAT altogether, and/or influenced those who could not access buprenorphine-naloxone to withdraw from treatment, rendering them vulnerable to related health harms [37, 90, 91]. Many of these restrictive practices seem to arise from organizational policies and structures that prioritize punishment and risk-reduction (e.g., diversion) over health concerns or care. As such, participants described a detrimental lack of agency and autonomy in regards to their OAT care. Such patient-centered care has been strongly advocated for and associated with improved outcomes, particularly for individuals with substance use problems, including OUD [92–95].

These factors highlight the need for a number of critical policy and operational improvements in the correctional system, including the need to standardize OAT provision and processes across institutions so that individuals can expect the same level of care that they would receive in the community [96]. Institutions should also expand access to a variety of evidence-based OAT formulations such as extended-release injectable buprenorphine (i.e., Sublocade) or antagonists (such as Naltrexone) which have been associated with positive outcomes among correctional populations and would improve patient-centered care [97–102]. Telehealth/telemedicine is another alternative approach to conventional care and a potential solution to improve access and quality of health care [103, 104]. These recommendations are warranted in the context of the ‘epidemic’ of opioid-related overdoses which has unfolded both across Canadian communities and correctional systems [19, 105–107]. While many of these OAT options are new and evidence on their effectiveness and feasibility among correctional populations is limited, literature points to positive outcomes [100, 108–112].

Notably, a recent internal evaluation of CSC’s healthcare services recommended improvements to the delivery, content, and monitoring of OAT programs, as well as the provision of adjunct addictions counseling, health-oriented education, and harm reduction programming [53]. Since this evaluation – and the present study’s data collection – CSC has further accelerated the roll-out of buprenorphine-naloxone as a first-line treatment option. Buprenorphine-naloxone-based OAT numbers are increasingly outpacing methadone-based OAT at many institutions [113]. Specifically, by January 2021, over half (62%) of the total 2481 individuals engaged in OAT in CSC institutions were receiving buprenorphine-naloxone, and 190 were receiving extended-release injectable buprenorphine [46]. Furthermore, a number of participants described using OAT for pain management, particularly as institutions would restrict certain medications (e.g., prescribed opioids). Since OAT is not necessarily meant for pain management, this has important implications for treatment programming, and underscores the need for individuals to have access to appropriate care (including pharmacotherapy) [26, 96]. CSC is in the process of developing chronic non-cancer pain management guidelines which should help this issue [114]. These practicalities may address some of the OAT-related issues identified by our study participants.

With regard to participants’ plans and perceived barriers and facilitators of community OAT transitions upon impending community release, the study’s findings corroborate many issues documented by other
studies among recently-released individuals with OUD. These include fear of exposure to drugs through peer networks resulting in the likelihood of relapse, financial, employment and housing instability, logistical (e.g., transportation) issues, and other barriers to effective community-based treatment continuation [88, 89, 115–119]. Furthermore, participants indicated a lack of clarity around their impending release details contributed to anxiety and an inability to adequately plan for OAT care and general reintegration. These observations underscore the need for timely, consistent, and collaborative community release planning and case management that takes personal readiness/motivation and key determinants of release outcomes into consideration towards setting individuals up for improved community reintegration and success [120]. Participants also expressed that an important facilitator to successful community reintegration was familial support; meanwhile, they indicated a main barrier would be returning to places where their families reside, possibly increasing the risks of exposure to deviant social networks and re-accessing or relapsing to substance use. While balancing these two factors may be difficult, many participants alluded that the critical factor would be personal motivation and/or self-efficacy, and that through CSC-based correctional programming (e.g., structured interventions that target risk factors directly linked to criminal behaviour in order to reduce reoffending) [121], they had learned the skills to combat their triggers and cravings, abstain from drug use, and continue with OAT care.

Overall, this study highlighted a variety of issues related to the administration of OAT within Ontario-based federal correctional institutions. However, results also indicate that OAT is beneficial and supports the reduction of opioid use and cravings among individuals with OUD, which will ideally translate into improved health, and more effective and successful post-release community reintegration. Importantly, correctional institutions offer a unique opportunity to provide OAT treatment for individuals with complex substance use histories, including OUD, who may otherwise not engage in treatment [80, 122, 123]. In addition, since most federally incarcerated individuals experience a period of community-based supervision which both allows and requires them to reintegrate into society, it is an opportune time to ensure continuous linkage of OAT and other necessary health and social supports during this high-risk transitional period [2].

Possible study limitations ought to be noted. While the study results reflect the participants’ self-reported experiences, they should be interpreted with appropriate caution as they may include inherent biases in self-report data (e.g., memory/recall/response bias, interpretation of questions, and social desirability). Additionally, participants may have had unconscious negativity biases that resulted in a tendency to report on and remember negative impacts and experiences over positive ones. These biases may be especially applicable to correctional study settings and/or populations, and related strict behavioral norms and/or potential repercussions related to rule-breaking (e.g., drug use, contraband, etc.). As such, participants may have downplayed their involvement in drug use or deviant institutional activities; at the same time, the study likely obtained an authentic empirical picture given its execution by an outside team independent of possible institutional consequences (e.g., coercion). The results are not generalizable, for CSC or other (including provincial) correctional populations as the study sample was small and cannot be considered representative. Study criteria to include those who had been in OAT care for at least 3 months was chosen to ensure individuals were stabilized; however, the sample and results might therefore have differed from those who were on the program for less than 3 months. Those who were screened and did not meet eligibility may have also differed in significant ways from the actual study sample. Moreover, the sub-sample of women was especially small, rendering an inability to conduct any sex/gender comparisons. Only around 6% of federally incarcerated individuals in Canada are women, and there is only one women’s prison in Ontario. As such, the limited number of women participants included was to be expected. However, similar sentiments towards OAT were provided by both sexes. Sex/gender differences should be better and systematically examined by future research.

Conclusions
The prevalence of OUD, and the need for effective OAT-based care in the Canadian federal correctional system is high. While general OAT access has expanded over-time, distinct structural and organizational factors appear to hinder OAT uptake and have resulted in adverse health and social outcomes. The study’s results point to a number of concrete recommendations. These include the elimination of waitlists, the standardization of OAT processes across institutions, a focus on patient-centered care that puts individuals at the forefront of their treatment decisions, the expansion of OAT formulations and telehealth care, and the need for more robust discharge planning to ensure individuals are adequately prepared for community release. Federal correctional institutions and policy makers should consider these suggestions in order to tangibly improve on the design, delivery, and practices of OAT care in Canadian prisons.
Appendix 1

Fig. 2  MAP

Table 4  Map and security classification levels of federal Correctional Service Canada institutions in Ontario

| Institution                              | Security Classification Levels                  |
|------------------------------------------|------------------------------------------------|
| Bath Institution                         | Medium Security Level                           |
| Beaver Creek Institution                 | Medium and Minimum Security Levels              |
| Collins Bay Institution                  | Maximum, Medium and Minimum Security Levels     |
| Grand Valley Institution for Women       | Multi Security Levels                           |
| Joyceville Institution                   | Medium and Minimum Security Levels              |
| Millhaven Institution                    | Maximum Security Level                          |
| Warkworth Institution                    | Medium Security Level                           |
Appendix 2
Qualitative Interview Guide

Qualitative questions

( NOTE: these questions and responses will be audiotaped)

24. Please DESCRIBE your experiences with OPIOID USE and DEPENDENCE PRIOR to your CURRENT incarceration period

Prompts:
○ How did your opioid use begin?
○ Has your opioid drug use changed over time?
○ Has opioid drug use impacted the following areas of your life: Health? Relationships? Work/Finances? Housing?

25. Please DESCRIBE your experiences with OST PRIOR to your CURRENT incarceration period

Prompts:
○ If you were engaged in OST prior to incarceration, how was the experience? What factors made the experience good or bad?
○ If you were not engaged in OST prior to incarceration, why not?

26. Please DESCRIBE your experiences with OPIOID and OTHER DRUG USE DURING your CURRENT incarceration period

Prompts:
○ Which opioids are available? What other drugs are available? Tell me about this.
○ Aside from your OST, which opioid-related supports/services are available? Which other drug use-related supports/services are available?
○ Have you used these supports/services? If so, tell me about your experiences with these.

27. Please DESCRIBE your experiences with OST DURING your CURRENT incarceration period

Prompts:
○ How did you first access OST? Tell me about your experience.
○ Are there any factors have been helpful to you? Is there anything you would change?

28. Please DESCRIBE your PERSONAL GOALS/PLANS (e.g., related to health, relationships, work/finances, housing) for your upcoming RELEASE into the community.

Prompts:
○ What are your general feelings towards your upcoming release into the community?
○ Is there anything you are looking forward to?
○ Is there anything you are worried about?

29. Please DESCRIBE your DRUG USE and OST-related GOALS/PLANS for your upcoming RELEASE into the community

Prompts:
○ What do you expect will happen with your opioid and/or other drug use following release?
○ What do you expect will happen with your OST following release?

30. Please DESCRIBE what FACTORS/SUPPORTS you see as particularly IMPORTANT in achieving your OPIOID USE and OST-related goals and plans upon RELEASE into the community

Prompts:
○ Is there something you feel is particularly important for helping you reach your drug use-related goals?
○ Is there something you feel is particularly important for helping you reach your OST-related goals?

31. Please DESCRIBE any potential CHALLENGES/BARRIERS you foresee towards achieving your OPIOID USE and OST-related goals and plans upon RELEASE into the community

Prompts:
○ Is there something you feel may make it particularly difficult to reach your drug use-related goals?
○ Is there something you feel may make it particularly difficult to reach your OST-related goals?

32. Please DESCRIBE where you see yourself a YEAR after your RELEASE into the community

Prompts:
○ Specifically regarding your opioid and/or other drug use?
○ Specifically regarding your OST?

Acknowledgements

The present study was conducted under a memorandum of understanding between Correctional Service Canada (CSC), Research Branch, and the Institute of Mental Health Policy Research, Centre for Addiction and Mental Health, on the basis of which CSC provided funding and logistical support for the study. The authors acknowledge temporary input and participation of Dr. Monica Malta to select aspects of the present study. The authors would also like to thank the individual research participants for their providing their expertise.

Authors’ contributions

All authors read and approved the final manuscript. CR co-led the study conceptualization; methodology; she led the project administration; investigation; data collection and curation; formal analysis; visualization; writing, reviewing, and editing. FN contributed to the methodology; formal analysis; visualization; writing, reviewing, and editing. MP contributed to the methodology; data collection and curation; formal analysis; writing, reviewing, and editing. SFM contributed to the conceptualization; methodology; resources; formal analysis; visualization; writing, reviewing, and editing. JR contributed to the conceptualization; methodology; resources; formal analysis; visualization; writing, reviewing, and editing. JR contributed to the conceptualization; funding acquisition; methodology; supervision; he contributed to visualization; writing, reviewing, and editing.

Authors’ information

Not applicable.

Funding

Dr. Rehm recognizes funding from Canadian Institutes for Health Research for the Ontario Node of the Canadian Research Initiative in Substance...
Misuse (CRISM) (Grant# SMN-139150). Prof. Fischer acknowledges research support from the Hugh Green Foundation Chair in Addiction Research, held at the Faculty of Medical and Health Sciences, University of Auckland, New Zealand.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to participants not providing consent to share their data beyond the research team, but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol and all procedures were approved by the Centre for Addiction and Mental Health (CAMH) Research Ethics Board (REB: #013–2018). Written informed consent was obtained from all subjects and all methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Institute for Mental Health Policy Research (IMHPR), Centre for Addiction and Mental Health (CAMH) & Canadian Research Initiative in Substance Misuse (CRISM), 33 Ursula Franklin St, Toronto, ON M5S 2S1, Canada. 2Research Branch, Correctional Service Canada, 340 Laurier Avenue West, Ottawa, ON, K1P 0P9, Canada. 3Department of Psychiatry, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. 4Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7, Canada. 5Campbell Family Mental Health Research InstituteCentre for Addiction and Mental Health, Toronto, ON, M5S 2S1, Canada. 6Institute of Medical Science (IMS), University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. 7Institut für Klinische Psychologie und Psychotherapie, Technische Universität Dresden, Chemnitzstr. 46, 01187 Dresden, Germany. 8Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Bol’Shaya Pirogovskaya Ulitsa, 19c1, Moscow, Russia 119146. 9Centre for Applied Research in Mental Health and Addiction (CARMHA), Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, V6B 5K3, Canada. 10School of Population Health and Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Grafton, Auckland, 1023, New Zealand. 11Department of Psychiatry, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.

Received: 24 June 2021 Accepted: 31 January 2022
Published online: 04 March 2022

References
1. Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725–39. https://doi.org/10.1111/add.13877.
2. Binswanger IA. Opioid use disorder and incarceration: hope for ensuring the continuity of treatment. N Engl J Med. 2019;380(13):1193.
3. Tsi J, Gu K. Utilization of addiction treatment among US adults with history of incarceration and substance use disorders. Addict Sci Clin Pract. 2019;14(1):9.
4. Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: a systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122–31.
5. Cope N. Drug use in prison: the experience of young offenders. Drugs. 2000;7(4):355–66.
6. Connor DP, Tewksbury R. Inmates and prison involvement with drugs: examining drug-related misconduct during incarceration. J Contemp Crim Justice. 2016;32(4):426–45.
7. Carpenter C, Royuela L, Montanari L, Davis P. The global epidemiology of drug use in prison. In: Drug use in prisoners: epidemiology, implications, and policy responses. New York: Oxford University Press, 2018. p. 17–41.
8. Terres M, Johnson S. Substance abuse problem severity, treatment readiness, and response bias among incarcerated men. Ottawa: Correctional Service Canada, 2014. Retrieved from: http://www.csc-ssc.gc.ca/005/008/092/rs13-05-eng.pdf.
9. Mullins P, Terres M, Farrell MacDonald S. Substance use on day of offence in a sample of male federal offenders. Ottawa: Correctional Service Canada, 2013. Retrieved from: http://www.csc-ssc.gc.ca/resear chc/005008-05-01-eng.shtml.
10. Garrel S, Farrell MacDonald S. Substance use patterns of men offenders: an ethnicultural comparison. Ottawa: Correctional Service Canada; 2019. Retrieved from: https://www.csc-ssc.gc.ca/research/rib-20-04-en.shtml.
11. Farrell MacDonald S, MacSwain M-A, Cheverie M, Tiemski M, Fischer B. Impact of methadone maintenance treatment on women offenders’ post-release recidivism. Eur Addict Res. 2014;20(4):192–9.
12. Canadian Institutes for Health Information (CIHI). Proposed standards for race-based and Indigenous identity and data collection and health reporting in Canada: Toronto, Ontario: Canadian Institutes for Health Information (CIHI); 2020. Retrieved from: https://www.cihi.ca/sites/default/files/document/proposed-standard-for-race-based-data-en.pdf.
13. Farrell MacDonald S, Gobel R, Biro SM, Ritchie MB, Curno J. Women offenders, substance use, and behavior. Ottawa: Correctional Service Canada; 2016. Retrieved from: https://www.csc-ssc.gc.ca/research/005008-35-eng.shtml.
14. Farrell MacDonald S. Comparing substance use patterns of aboriginal and Non-aboriginal women offenders. Ottawa: Correctional Service Canada; 2014. Retrieved from: https://www.csc-ssc.gc.ca/006/008/092/rs14-26-eng.pdf.
15. Cram S, Farrell-Macdonald S. Comparison of women offenders who use opioids versus other types of substances. Ottawa: Correctional Service Canada; 2019. Retrieved from: https://www.csc-ssc.gc.ca/005/008/092/rib-19-09-en.pdf.
16. Kouyoumdjian F, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Can J Public Health. 2014;105(3):e198–202.
17. Johnson S, Farrell MacDonald S, Cheverie M, Myrick C, Fischer B. Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada. Drug Alcohol Depend. 2012;124(1–2):172–6.
18. MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (mmt) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2014;41(3):380–94.
19. McKendry L, Biro S, Keown LA. Overdose Incidents in cedral Custody, 2012/2013–2016/2017, 2018. Ottawa, Ontario: Correctional Service Canada. Retrieved from: https://www.csc-ssc.gc.ca/research/092/sr-18-02-en.pdf.
20. Correctional Service Canada. Guidance on opioid agonist treatment (OAT). Ottawa: Correctional Service Canada, 2020. Retrieved from: https://www.csc-ssc.gc.ca/health/002006-3004-en.shtml#bvdid=true.
21. Bruneau J, Ahamad K, Goyer M-E, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247–57.
22. Scotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727–40.
23. Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
24. Nielsen S, Larance B, Degenhardt L, Gowling W, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people: John Wiley & Sons, Ltd; 2016. Retrieved from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011172.pub2/abstract.
25. Santos T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–93.
26. Lines R. From equivalence of standards to equivalence of objectives: the entitlement of prisoners to health care standards higher than those outside prisons. Int J Prison Health. 2006;2(4):269–80.

27. Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus. 2020;41(2):150–4.

28. United Nations Office on Drugs and Crime (UNODC). The United Nations standard minimum rules for the treatment of prisoners (The Nelson Mandela Rules). Vienna: United Nations Office on Drugs and Crime (UNODC), 2015. Retrieved from: https://www.unodc.org/docum ents/justice-and-prison-reform/GA-RESOLUTION_E_ebook.pdf

29. Sander G, Shirley-Beavan S, Stone K. The global state of harm reduction in prisons. J Correct Health Care. 2019;25(2):105–20.

30. Bone C, Eysenbach L, Bell K, Barry DT. Our ethical obligation to treat opioid use disorder in prisons: a patient and physician’s perspective. J Med Law Ethics. 2018;46(2):268–71.

31. Grella CE, Ostile E, Scott CK, Dennis M, Carnavale J. A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768.

32. Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. The effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abus Treat. 2019;99:32–43.

33. Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, Boss R, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–7.

34. Vestal C. At Rikers Island, a legacy of medication-assisted opioid treatment. New York: The Pew Charitable Trusts, 2016. Retrieved from: https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/05/23/at-rikers-island-a-legacy-of-medication-assisted-opioid-treatment.

35. Sharma A, O’Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Schwartz RP. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abus Rehabil. 2016;7:27–40.

36. Johnson S, Rasul MA, Iqbal J, Grant BA. Institutional methadone maintenance treatment. Impact on release outcome and institutional behaviour. Ottawa: Correctional Service Canada, 2001. Retrieved from: http://www.csc-ssc.gc.ca/text/rshcr/reports/119/119_e.pdf

37. MacSwain MA, Cheverie M. Comparing the mental health treatment and abuse histories of men and women methadone maintenance treatment program (MWTP) participants. Ottawa: Correctional Service Canada, 2012. Retrieved from: http://www.csc-ssc.gc.ca/research/005008-rs12-9-eng.shtml

38. MacSwain MA, Farrell MacDonald S, Cheverie M, Fischer B. Assessing the impact of methadone maintenance treatment (MMT) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav. 2013;41(3):380–94.

39. Correctional Service Canada. CSC Statistics - Key Facts and Figures. Ottawa: Government of Canada, 2017. Retrieved from: http://www.csc-ssc.gc.ca/publications/005007-3024-eng.shtml

40. Lanoie LO. Opioid substitution therapy in Canada’s prisons. Can J Addict. 2015;6(3):5–7.

41. Correctional Service Canada. Opioids: Ottawa Correctional Service Canada; 2019. Retrieved from: https://mail.google.com/mail/u/0/a/1/inbox

42. Correctional Service Canada. Opioid Agonist Treatment: Ottawa: Correctional Service Canada, 2021. Retrieved from: https://www.csc-ssc.gc.ca/health/002006-3000-en.shtml

43. Perry AE, Neilson M, James M-S, Glanville JM, Woodhouse R, Godfrey C, et al. Pharmacological interventions for drug-using offenders. Cochrane Database Syst Rev. 2015;6:CD010862.

44. Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. "From the prison door right to the sidewalk, everything went downhill," a qualitative study of the health experiences of recently released inmates. Int J Psychiatry. 2011;34(4):249–55.

45. Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. From the prison door right to the sidewalk, everything went downhill," a qualitative study of the health experiences of recently released inmates. Int J Psychiatry. 2011;34(4):249–55.

46. Motiuk L, Vuong B. Development and validation of a criminal risk index (CRI) for federally sentenced offenders in Canada. Ottawa: Correctional Service of Canada; 2018. Retrieved from: https://www.csc-ssc.gc.ca/acts-and-regulations/705-6-cd-en.html

47. Correctional Service Canada. Opioids: Ottawa Correctional Service Canada; 2013. Retrieved from: https://www.csc-ssc.gc.ca/oms/004009-0001-eng.shtml

48. Correctional Service Canada. Commissioner’s Directive 705-6: Correctional planning and criminal profile. Ottawa: Correctional Service Canada; 2018. Retrieved from: https://www.csc-ssc.gc.ca/acts-and-regulations/705-6-cd-en.html

49. Motiuk L, Vuong B. Development and validation of a criminal risk index (CRI) for federally sentenced offenders in Canada. Ottawa: Correctional Service of Canada; 2018. Retrieved from: https://www.csc-ssc.gc.ca/research/r-403-en.shtml

50. Kincaid D, Grant BA. The computerized assessment of substance abuse (CASA): Results from the demonstration project. Ottawa: Correctional Service Canada; 2006. Retrieved from: https://www.csc-ssc.gc.ca/research/173-eng.shtml

51. Creswell JW, Creswell JD. Research design: qualitative, quantitative, and mixed methods approaches: Sage publications; 2017.

52. Williams M, Moser T. The art of coding and thematic exploration in qualitative research. Int J Qual Res. 2019;15(1):45–55.
68. O'Connor C, Joffe H. Intercoder reliability in qualitative research: debates and practical guidelines. Int J Qual Methods. 2020;19(6):105618.
69. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–907.
70. Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):14008.
71. Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871–81.
72. Department of Justice Canada. Spotlight on Gladue: challenges, experiences, and possibilities in Canada’s criminal justice system. Ottawa: Government of Canada; 2019. Retrieved from https://www.justice.gc.ca/eng/pr-pr/jr/glادue/p2.html.
73. Boyd S, MacPherson D. Vancouver area network of drug users: community engagement – the harms of drug prohibition: ongoing resistance in Vancouver’s downtown eastside. BC Stud. 2019;20:87–96.
74. Fischer B. Prohibition, public health and a window of opportunity: an analysis of Canadian drug policy, 1985–1997. Policy Stud. 1999;20(3):197–210.
75. Monaco L, Gryczynski J, Lee JD, Dusek K, McDonald R, Malone M, et al. Exploring nonprescribed use of buprenorphine in the criminal justice system through a series of qualitative interviews among individuals recently released from incarceration. J Subst Abus Treat. 2020;108:267.
76. Bucersiu SM, Haggerty KD. Fentanyl behind bars: the implications of synthetic opiates for prisoners and correctional officers. Int J Drug Policy. 2019;71:133–8.
77. van der Meulen E. “It goes on everywhere”: injection drug use in Canadian federal prisons. Subst Use Misuse. 2017;52(7):884–91.
78. Ahmed R, Angel C, Martel R, Pyne D, Keenan L. Access to healthcare services during incarceration among female inmates. Int J Prison Health. 2016;12(4):204–15.
79. Plugge E, Douglas N, Fitzpatrick R. Patients, prisoners, or people? Women prisoners’ experiences of primary care in prison: a qualitative study. Br J Gen Pract. 2008;58(554):e1–8.
80. Fiscella K, Wakeman SE, Belketsky L. Implementing opioid agonist treatment in correctional facilities. JAMA Intern Med. 2018;178(9):1153–4.
81. West Coast Prison Justice Society. West Coast Prison Justice Society files human rights complaint against Correctional Service Canada on behalf of federal prisoners with opioid use disorder. Vancouver: West Coast Prison Justice Society (WCPS); 2018. Retrieved from https://prisonjustice.org/wp-content/uploads/2018/12/OST-rep-complaint-to-CRC-20180804-narrative-1.pdf.
82. The College of Physicians and Surgeons of Ontario. Methadone maintenance treatment: Program standards and clinical guidelines. Toronto: College of Physicians and Surgeons of Ontario; 2011. Retrieved from http://www.cpos.on.ca/uploaded_files/members/MMT-Guidelines.pdf.
83. Csete J. Criminal justice barriers to treatment of opioid use disorders in the United States: the need for public health advocacy. Am J Public Health. 2019;109(3):419–22.
84. The Lancet Public Health. A public health approach to Canada’s opioid crisis. Lancet Public Health. 2018;3(5):e204.
85. Gryczynski J, Jaffe JH, Schwartz RP, Dulée K, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285–91.
86. Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine/naltrexone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014;46(5):412–26.
87. Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Peterson JA, Reisinger HS, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17(5):396–401.
88. Fox AD, Maradiaga J, Weiss L, Sanchez J, Strables JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.
89. Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.
90. Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–9.
91. Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–3.
92. Davis EL, Kelly PJ, Deane FP, Baker AL, Buckingham M, Degan T, et al. The relationship between patient-centered care and outcomes in specialist drug and alcohol treatment: a systematic literature review. Subst Abus. 2020;41(2):216–31.
93. Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Jeekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2019;14(1):37.
94. Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;15(1):7.
95. Trujillo J, González-Saiz F, Manresa MJ, Alcaraz S, Batlle D, Duran-Sindreu S, et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: the role of perceived participation in dosage decisions. Patient Educ Couns. 2017;100(3):981–6.
96. Lunny SE, Dolan K. Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Aust NZ J Public Health. 2008;32(1):86–7.
97. Waddell EN, Springer SA, Marsh LA, Farabee D, Schwartz RP, Nyaku A, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJ-involved adults (ENT-CJS). J Subst Abus Treat. 2021;126:108389.
98. Vorspan F, Hjelmstrom P, Simon N, Benyamina A, Dervaux A, Brousse G, et al. What place for prolonged-release buprenorphine depot-formulation Bupvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907–14.
99. Gordon MS, Voci FJ, Taxman F, Fishman M, Sharma B, Blue TR, et al. A randomized controlled trial of buprenorphine for probationers and parolees: bridging the gap into treatment. Contemp Clin Trials. 2019;79:21–7.
100. Gordon MS, Voci FJ, Fitzgerald TT, O’Grady KE, O’Brien CP. Extended-release naltrexone for pre-release prisoners: a randomized trial of medical mobile treatment. Contemp Clin Trials. 2017;53:130–6.
101. Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, et al. Managing opioid use disorder in primary care: PEER simplified guideline. Can Fam Physician. 2019;65(S5):321–30.
102. Bahjí A, Carlone D, Altomare J. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction. 2020;115(8):1413–25.
103. Tian EJ, Venugopalan S, Kumar S, Beard M. The impacts of and outcomes from telehealth delivered in prisons: a systematic review. Plos One. 2021;16(5):e0251840.
104. Edge C, Black G, King E, George J, Patel S, Hayward A. Improving care quality with prison telemedicine: the effects of context and multiplicity on successful implementation and use. J Telemed Telecare. 2019;27(6):325–42.
105. Government of Canada. Opioid- and stimulant-related harms in Canada. 2020. Ottawa: Government of Canada. Retrieved from https://health-infobase.canada.ca/substance-related-harms/opioids/maps?index=1
106. Ksak M, Montague BT, Trowbridge P, Johnson SC, Binswanger IA. Opioid use and chronic infections: The value of addressing the syndemic in correctional settings via telemedicine: Guidance and broader use of long-acting medications. J Infect Dis. 2020;222(Supplement_5):S486–93.
107. Caukkins JP, Gould A, Pardo B, Reuter R, Stein BD. Opioids and the criminal justice system: new challenges posed by the modern opioid epidemic. Annu Rev Crim. 2021;41(1):553–75.
108. Gordon MS, Mitchell SG, Blue TR, Voci FJ, Fishman MJ, Murphy SM, et al. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. J Subst Abus Treat. 2020;108:341.
109. Gordon MS, Kinlock TW, Voci FJ, Fitzgerald TT, Memisoglu A, Silverman B. A phase 4 pilot, open-label study of VMTROL®(extended-release naltrexone XR-NTX) for prisoners. J Subst Abus Treat. 2015;59:52–8.
110. Springer SA, Altice FL, Brown S-E, Di Paola A. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158–65.

111. Schwartz RP, Mitchell MM, O'Grady KE, Kelly SM, Goyczynski J, Mitchell SG, et al. Pharmacotherapy for opioid addiction in community corrections. Int Rev Psychiatry. 2018;30(5):117–35.

112. Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008–14.

113. Correctional Service Canada. Opioid agonist treatment. Ottawa: Correctional Service Canada; 2019. Retrieved from: [https://www.csc-scc.gc.ca/health/002006-2007-en.shtml](https://www.csc-scc.gc.ca/health/002006-2007-en.shtml)

114. Correctional Service Canada. Promoting wellness and independence of older persons in CSC custody: A policy framework. Pain Management. Ottawa: Correctional Service Canada; 2018. Retrieved from: [https://www.csc-scc.gc.ca/publications/005007-1601-en.shtml#6.8](https://www.csc-scc.gc.ca/publications/005007-1601-en.shtml#6.8)

115. Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(3).

116. Lee J, Gordon M, Friedmann P, Nunes E, O'Brien C. Extended-release naltrexone to prevent opioid relapse among adults with criminal justice system involvement. Am J Addict. 2016;25(4):345.

117. Begun AL, Early TJ, Hodge A. Mental health and substance abuse service engagement by men and women during community reentry following incarceration. Adm Policy Ment Health Ment Health Serv Res. 2016;43(2):207–18.

118. Martin RA, Gresko SA, Brinkley-Rubinstein L, Stein LA, Clarke JG. Post-release treatment uptake among participants of the Rhode Island Department of Corrections comprehensive medication assisted treatment program. Prev Med. 2019;128:105766.

119. Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8.

120. Canzater SL, LaBelle RM. Championing change to save lives: a call to action to implement reforms to increase use of medications to treat opioid use disorder in correctional settings. Crim Justice Rev. 2020;0(0):0734016820981629.

121. Correctional Service Canada. Correctional programs. Ottawa: Correctional Service Canada; 2019. Retrieved from: [https://www.csc-scc.gc.ca/002/002-0001-en.shtml](https://www.csc-scc.gc.ca/002/002-0001-en.shtml)

122. Macmadu A, Rich JD. Correctional health is community health. Issues Sci Technol. 2015;52(1).

123. Beletsky L. Treating substance use and mental health disorders in correctional settings: Northeastern University of Law; 2019. Retrieved from: [https://papers.ssm.com/sol3/papers.cfm?abstract_id=3499365](https://papers.ssm.com/sol3/papers.cfm?abstract_id=3499365)

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions